209 results on '"Coco, Francesco Lo"'
Search Results
2. High Doses of Vitamin C and Leukemia: In Vitro Update
3. Thrombo-hemorrhagic deaths in acute promyelocytic leukemia
4. Vitamin C Against Cancer
5. Acute Promyelocytic Leukemia : Perspective 2
6. Minimal Residual Disease in Acute Promyelocytic Leukemia
7. Molecular signature of retinoic acid treatment in acute promyelocytic leukemia
8. Retinoic acid targets DNA-methyltransferases and histone deacetylases during APL blast differentiation in vitro and in vivo
9. Molecular characterization of a t(1;3)(p36;q21) in a patient with MDS. MEL1 is widely expressed in normal tissues, including bone marrow, and it is not overexpressed in the t(1;3) cells
10. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias?
11. Cardiovascular events in cancer survivors
12. GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children
13. Evaluation of the prognostic relevance of L-selectin and ICAM1 expression in myelodysplastic syndromes
14. Alterations of a zinc finger-encoding gene, BLC-6, in diffuse large-cell lymphoma
15. Choice of chemotherapy in induction, consolidation and maintenance in acute promyelocytic leukaemia
16. Different mechanisms lead to a karyotypically identical t(20;21) in myelodysplastic syndrome and in acute myelocytic leukemia
17. Obesity is a risk factor for acute promyelocytic leukemia: evidence from population and cross-sectional studies and correlation with FLT3 mutations and polyunsaturated fatty acid metabolism
18. Extranodal Lymphomas Associated With Hepatitis C Virus Infection
19. Therapy-related myelodysplastic syndrome–acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem
20. High Doses of Vitamin C and Leukaemia: In Vitro Update
21. Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party
22. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups: Presented in part at the 41st meeting of the American Society of Hematology, New Orleans, LA, December 3-7, 1999.
23. Therapy of Molecular Relapse in Acute Promyelocytic Leukemia
24. Genetic Diagnosis and Molecular Monitoring in the Management of Acute Promyelocytic Leukemia
25. High-resolution molecular allelokaryotyping identifies novel genomic alterations in acute promyelocytic leukemia (APL)
26. Immunophenotyping of acute myeloid leukaemia: Relevance of analysing different lineage-associated markers
27. Acute Promyelocytic Leukemia
28. Minimal Residual Disease in Acute Promyelocytic Leukemia
29. Risk-Adapted, MRD-Refined Therapeutic Approach for the Treatment of Acute Myeloid Leukemia: From a Single Center Experience to the Cooperative Gimema Protocol AML1310
30. A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients
31. GIMEMA-AIEOP AIDA Protocols for the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL) In Children: Analysis of 247 Patients Enrolled In Two Sequential Italian Multicenter Trials
32. MRD-Directed Post-Remissional Therapy Dramatically Improves Outcome of Adult Patients with High Risk AML by Implementing Allogeneic Transplant Option
33. A Simple Clinical Prognostic Scoring System for Newly Diagnosed Cytogenetically Normal Acute Myeloid Leukemia: a Retrospective Analysis on 530 Patients
34. Abstract 656: High-resolution molecular allelokaryotyping identifies novel genomic alterations in acute promyelocytic leukemia (APL)
35. In Acute Myeloid Leukemia, the Use in Induction of Standard Dose Arac Is Associated with a Better Quality of Response as Compared to An Induction Regimen Containing High Dose Arac.
36. Peptide-Vaccine Treatment Associated with TKI Therapy in Patients with CML Is Able to Induce Immunologic, Cytogenetic and Molecular Responses: a Single Center Experience with Long-Term Follow up.
37. Monitoring of minimal residual disease in acute myeloid leukemia
38. The Amount of Mitochondrial Apoptosis Exerts Prognostic Impact on Normal Karyotype Acute Myeloid Leukemia.
39. Decisional Algorithm to Incorporate Hematopoietic Stem Cell Transplantation in the Management of Adult Patients with Acute Myeloid Leukaemia.
40. Evaluation of the prognostic relevance of l‐selectin and ICAM1 expression in myelodysplastic syndromes
41. Detection of Minimal Residual Disease by Flow-Cytometry Otimizes Risk Stratification When Combined with Cytogenetics in AML.
42. The High Prevalence of FLT3-ITD Mutations Is Associated with the Poor Outcome in Adult Patients with t(6;9)(p23;q34) Positive AML - Results of an International Metaanalysis.
43. Variable but Consistent Pattern of Meningioma 1 Gene (MN1) Expression in Different Genetic Subsets of Acute Myelogenous Leukaemia and Its Potential Use as Marker for Minimal Residual Disease Detection.
44. “Fulminant” Acute Promyelocytic Leukemia: Clinical and Biological Features.
45. Optimal Post-Remission Therapy for Flow-Cytometry Minimal Residual Disease Positive Patients with Acute Myeloid Leukemia.
46. Multidrug Resistance Proteins Overexpression Worsen the Favorable Clinical Impact of an Elevated Spontaneous Apoptosis in Acute Myeloid Leukemia (AML).
47. Arsenic Trioxide (ATO) and MEK1 Inhibitor Activate Apoptotic p73 Pathway in Primary Acute Myelogenous Leukemia Blasts.
48. Spontaneous Apoptosis and Proliferation Predict Disease Progression within ZAP-70 Negative B-Cell Chronic Lymphocytic Leukemia (B-CLL).
49. Imatinib-mesylate for all patients with hypereosinophilic syndrome?
50. High-mobility group A1 proteins are overexpressed in human leukaemias
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.